Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biochem Pharma (BCHE) -- Ignore unavailable to you. Want to Upgrade?

To: Steven Yang who wrote (679)	11/1/1999 8:43:00 AM
From: JDN	Read Replies (1) \| Respond to of 783

To all: Here is another country approval. JDN LAVAL, Quebec, Canada, Nov. 1st /CNW/ - BioChem Pharma Inc. (NASDAQ: BCHE; ME, TSE: BCH) announced today that approval has been received from the Department of Health in Taiwan to market Zeffix (lamivudine), the first effective oral treatment for chronic hepatitis B discovered by BioChem Pharma and marketed by Glaxo Wellcome. Zeffix is indicated for the treatment of patients, 16 years of age or older, with chronic hepatitis B and evidence of viral replication. In addition to significantly reducing liver inflammation, Zeffix has been shown in clinical trials to produce, after three years of continued treatment, seroconversion(x) rates of 65% in patients with active liver disease(xx) and 40% in the overall patient group. According to World Health Organization estimates, approximately 350 million people around the world are long-term (chronic) carriers of the hepatitis B virus (HBV), including more than 2.5 million people in Taiwan. Zeffix is already available in a number of countries including the US (as Epivir- HBV), Canada (as Heptovir), South Korea, the European Union and was recently launched for sale in China (as Heptodin). Under agreement, BioChem Pharma receives royalties from Glaxo Wellcome on sales of lamivudine for use in both HIV/AIDS (3TC/Epivir/Combivir) and HBV (Zeffix/Epivir-HBV/Heptovir/Heptodin). Glaxo Wellcome has the right to develop, manufacture and sell lamivudine worldwide, except in Canada, where BioChem Pharma and Glaxo Wellcome have formed a commercialization partnership. BioChem Pharma is an international biopharmaceutical company dedicated to the research, development and commercialization of innovative products for the prevention and treatment of human diseases with a focus in the anti-infective and anticancer areas. Epivir, 3TC, Combivir, Zeffix, Epivir-HBV, Heptovir and Heptodin are trademarks of the Glaxo Wellcome Group of Companies. BioChem Pharma news releases and other company information can be found on the World Wide Web at www.biochempharma.com.